Abstract
The central and peripheral vascular haemodynamic effects of glucagon were studied in 29 patients. With a single dose method of 2 or 5 mg. glucagon intravenously the inotropic action of the drug produced immediate increased myocardial contractility with significant increase in cardiac output and enhanced cardiac performance, and lowering of pulmonary arterial pressure and pulmonary vascular resistance. No primary peripheral vascular effect was evident, and the increased systemic pressure and lowered systemic resistance appear to be secondary to the central action of the drug. With the dosage used there were no undesirable side-effects apart from a feeling of slight nausea. Though the haemodynamic effects are abrupt, reaching their maximum values in the first 10 minutes after injection, they tend to be dissipated within half an hour, presumably due to the very rapid destruction of the drug. Repeated booster doses rather than continuous infusion may be the method of choice to maintain an increased cardiac output. The positive chronotropic action of the drug may cause transient palpitations. Glucagon increased the cardiac output in the acute phase of myocardial infarction by 42 per cent. The haemodynamic effects in chronic rheumatic heart disease are more varied, and it may increase left atrial pressure in mitral stenosis, which is undesirable. Hyperglycaemia results from liver glycogenolysis but blood sugar levels rarely exceeded 200 mg./100 ml. These results warrant further study of the value of glucagon as a positive inotropic agent in low output heart failure, especially in acute myocardial infarction with cardiogenic shock, or after cardiac surgery, or in unrelieved chronic congestive heart failure.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brogan E., Kozonis M. C., Overy D. C. Glucagon therapy in heart-failure. Lancet. 1969 Mar 8;1(7593):482–484. doi: 10.1016/s0140-6736(69)91587-6. [DOI] [PubMed] [Google Scholar]
- FARAH A., TUTTLE R. Studies on the pharmacology of glucagon. J Pharmacol Exp Ther. 1960 May;129:49–55. [PubMed] [Google Scholar]
- GREENFIELD A. D., WHITNEY R. J., MOWBRAY J. F. Methods for the investigation of peripheral blood flow. Br Med Bull. 1963 May;19:101–109. doi: 10.1093/oxfordjournals.bmb.a070026. [DOI] [PubMed] [Google Scholar]
- Glick G., Parmley W. W., Wechsler A. S., Sonnenblick E. H. Glucagon. Its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol. Circ Res. 1968 Jun;22(6):789–799. doi: 10.1161/01.res.22.6.789. [DOI] [PubMed] [Google Scholar]
- Hoak J. C., Connor W. E., Warner E. D. Toxic effects of glucagon-induced acute lipid mobilization in geese. J Clin Invest. 1968 Dec;47(12):2701–2710. doi: 10.1172/JCI105953. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lal S., Fletcher E. Glucagon therapy in heart-failure. Lancet. 1969 Apr 5;1(7597):731–731. doi: 10.1016/s0140-6736(69)92681-6. [DOI] [PubMed] [Google Scholar]
- Linhart J. W., Barold S. S., Cohen L. S., Hildner F. J., Samet P. Cardiovascular effects of glucagon in man. Am J Cardiol. 1968 Nov;22(5):706–710. doi: 10.1016/0002-9149(68)90209-9. [DOI] [PubMed] [Google Scholar]
- Lucchesi B. R. Cardiac actions of glucagon. Circ Res. 1968 Jun;22(6):777–787. doi: 10.1161/01.res.22.6.777. [DOI] [PubMed] [Google Scholar]
- REGAN T. J., LEHAN P. H., HENNEMAN D. H., BEHAR A., HELLEMS H. K. MYOCARDIAL METABOLIC AND CONTRACTILE RESPONSE TO GLUCAGON AND EPINEPHRINE. J Lab Clin Med. 1964 Apr;63:638–647. [PubMed] [Google Scholar]
- SARNOFF S. J., BRAUNWALD E., WELCH G. H., Jr, CASE R. B., STAINSBY W. N., MACRUZ R. Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index. Am J Physiol. 1958 Jan;192(1):148–156. doi: 10.1152/ajplegacy.1957.192.1.148. [DOI] [PubMed] [Google Scholar]